The effects of India’s COVID-19 lockdown on critical non-COVID health care and outcomes: Evidence from dialysis patients

Radhika Jain a,*, Pascaline Dupas b

a Shorenstein APARC, Stanford University, Stanford, CA, 94305-6055, USA
b Department of Economics, Stanford University, Stanford, CA, 94305-6055, USA

ARTICLE INFO

Keywords:
COVID-19
Pandemic
Non-pharmaceutical intervention
Excess mortality
Non-communicable disease
Dialysis
Chronic kidney disease
Health systems

ABSTRACT

India’s COVID-19 lockdown, one of the most severe in the world, is widely believed to have disrupted critical non-COVID health services. However, linking these disruptions to effects on health outcomes has been difficult due to the lack of reliable, up-to-date health outcomes data. We identified all dialysis patients under a statewide health insurance program in Rajasthan, India (N = 2110), and conducted surveys to examine the effects of the lockdown on non-COVID care access and health outcomes. Post-lockdown mortality was our primary outcome and morbidity and hospitalization were secondary outcomes. 63% of patients experienced a disruption to their care. Transport barriers, hospital service disruptions, and difficulty obtaining medicines were the most common causes. We compared monthly mortality in the four months after the lockdown with pre-lockdown mortality trends, as well as with mortality trends for a similar cohort in the previous year. Mortality in May 2020, after a month of exposure to the lockdown, was 1.70 percentage points (95% CI 0.01–0.03) or 64% higher than in March 2020 and total excess mortality between April and July was estimated to be 22%. A 1SD increase in an index of care disruptions was associated with a 0.175SD (95% CI 0.13–0.22) increase in a morbidity index, a 3.1 percentage point (95% CI 0.012–0.051) increase in hospitalization, and a 2.1 percentage point (95% CI 0.00–0.04) increase in probability of death between May and July. Females, socioeconomically disadvantaged groups, and patients living far from the health system faced worse outcomes. The results highlight the unintended consequences of the lockdown on critical, life-saving non-COVID health services that must be taken into account in the implementation of future policy efforts to control the spread of pandemics.

1. Introduction

On March 24, 2020, the Government of India ordered one of the most stringent nationwide COVID-19 lockdowns in the world to control virus spread (Hale et al., 2020). The lockdown was announced with 4 h’ notice, barred people from leaving their homes, required non-essential commercial establishments and transport services to close, and was enforced strictly with penalty of arrest (Ministry of Home Affairs, 2020). National restrictions were eased 10 weeks later, at the beginning of June, but localized restrictions continued in areas with high case counts. Although critical health services were officially exempt from the lockdown, the media reported widespread disruptions to routine and emergency non-COVID care due to transport and curfew barriers for patients and health workers, hospitals turning patients away, and supply chain disruptions that affected medicine access and costs (Indian Express, 2020; IndiaSpend, 2020; New York Times, 2020). Medical services under government health insurance programs across the country decreased by 51% and the national Health Management Information System (HMIS), which collates monthly reports from the public health system, reported dramatic decreases in preventive and curative care (IndiaSpend, 2020a; Smith et al., 2020).

A second wave of COVID-19 infections engulfed India in 2021, with the country reaching close to 400,000 new cases daily in early May 2021, far exceeding the first in magnitude (Johns Hopkins 2021). In part, due to the perceived costs of the first lockdown, the government eschewed nationwide lockdowns in favor of localized curfews and closures in COVID-19 hotspots. Nevertheless, the health system has been overwhelmed by the surge, though the economic costs have been more muted (The Lancet, 2021; Indian Express, 2021).

Lockdowns can help “flatten the curve” of new infections, buying the health system time to prepare for and respond to the pandemic (Viguerie et al., 2020; Flaxman et al., 2020; Islam et al., 2020). Recent
research suggests India’s 2020 lockdown reduced the growth in COVID-19 incidence, largely by restricting mobility (Thayer et al., 2020). However, the indirect costs of restricting mobility and economic activity may be sizeable (Douglas et al., 2020; Haug et al., 2020). In India, these costs were exacerbated by the hasty imposition of the lockdown, which gave the health system and households little time to prepare (The Lancet, 2020; Cash and Patel, 2020). People with chronic health conditions are particularly vulnerable to pandemic-related care disruptions (Modesti et al., 2020). Largescale, quantitative vidence of disruptions to non-COVID health care during the 2020 lockdown is now emerging from around the country, particularly for chronic conditions like cancer, kidney disease, diabetes, and tuberculosis, but their health impacts have not been measured (Cilloni et al., 2020; Jain et al., 2021; Kusuma et al., 2021; Ranganathan et al., 2021; Singh et al., 2021). Careful measurement of the indirect morbidity and mortality effects of the lockdown is critical to understanding the full consequences of the pandemic and how to prepare health systems better for future disease outbreaks (Beaney et al., 2020; Kiang et al., 2020; Setel et al., 2020).

Quantifying the impacts of such disruptions on morbidity and mortality has been difficult in the Indian context due to the unavailability of reliable and high frequency data measuring health outcomes and cause-specific mortality. Because the COVID-19 lockdown may have reduced deaths from some causes, such as road accidents, evaluating its effects requires disaggregated cause-specific mortality. The vast majority of deaths in India occur at home, rather than at health facilities, are not required in the national Civil Registration System, and have no certified cause of death (Jha et al., 2005). While government health insurance programs collect real-time data on hospital services provided, they record no details on patient morbidity or mortality. The HMIS data are typically of low quality, underrepresent care in the private sector, and do not provide complete morbidity or mortality outcomes (Sharma et al., 2016). The Sample Registration System, which estimates age-specific death rates through population surveys, does not provide details on cause of death and the most recent report only provides total mortality estimates through 2018 (SRS Bulletin).

The objective of this study was to evaluate the extent to which the lockdown impacted morbidity and mortality for critical chronic care patients. Given the dearth of reliable, updated, and publicly available data on health outcomes in India, evaluating the effect of the COVID-19 lockdown on non-elective health services requires the identification of patients in need of such care and the collection of primary data. We used insurance claims filed under a largescale government health insurance program to identify patients requiring dialysis, a form of non-elective chronic care, during the lockdown. We conducted phone surveys with their households to estimate the effects of the lockdown on health care access and on morbidity, hospitalization, and mortality in the four months following its imposition. To our knowledge, this is one of the first studies to measure the effects of India’s 2020 COVID-19 lockdown on excess mortality from a non-COVID health condition. Quantifying the trade-off between averted COVID-19 mortality and the non-COVID-19 costs of the lockdown is beyond the scope of this paper.

1.1. Dialysis in India

We focused on dialysis, a form of life-sustaining long-term hospital care for patients with end stage chronic kidney disease (CKD). CKD is the 12th leading cause of deaths globally and 8th in India (Bikbov et al., 2020). Although access to dialysis treatment is relatively low, the expansion of government health insurance has increased its reach. Dialysis removes waste, salts, and excess water to prevent their build up in the body; regulates levels of potassium, sodium, and bicarbonate in the blood; and controls blood pressure. The typical patient requires three-to-4 h sessions, two to four times each week for the duration of their life or until they get a kidney transplant. Disruptions to dialysis treatment result in the accumulation of fluids and toxins in the body, and can cause extreme swelling, nausea and vomiting, difficulty in breathing and urinating, and other symptoms. Missing dialysis visits or shortening their duration is associated with large increases in hospitalization and mortality (Anderson et al., 2009; Abdel-Kader and Unruh, 2009; Saran et al., 2003; Zoraster et al., 2007). Recent work documents substantial disruptions to dialysis care in India during the lockdown, but does not link them to health outcomes (Ramachandran and Jha, 2020; Prasad et al., 2020; Smith et al., 2020).

2. Methods

2.1. Study population and data

We study care-seeking and health outcomes before and after the imposition of the COVID-19 lockdown. The study population was all dialysis patients enrolled in a government health insurance program that covers the poorest two-thirds of Rajasthan’s population. The Ayushman Bharat Mahatma Gandhi Rajasthan Swasthya Bima Yojana (AB-MGRSBY), is a state-wide government health insurance program in Rajasthan, India. It entitles approximately 50 million low-income individuals to free secondary and tertiary care at over 1200 empaneled hospitals. Household eligibility is based on state poverty lists. All members are automatically enrolled and face no premium, deductible, or copay. Hospitals file claims in real-time for every patient visit through the government’s electronic filing system. These claims data, which include patient name, phone number, address, hospital visited, and services received, provide one of the only ways of directly identifying patients utilizing hospital care in Rajasthan.

We obtained access to all administrative claims data filed under the program from its launch in 2015 through October 2019. Using the last 3 months of these data, we identified all patients on dialysis under insurance between August and October 2019. Because dialysis is long-term and non-elective care, patients on dialysis in late 2019 would continue to require it through the COVID-19 lockdown if still alive. Therefore, these patients provide an ideal group to study the effects of the lockdown on critical chronic care.

To collect data on health care access and outcomes through the lockdown period, we conducted phone surveys using patient contact numbers in the administrative records. The survey was conducted with the patient or the person in the household most knowledgeable of their care if the patient was unwell or dead, and collected data on dialysis visits in the month prior to the lockdown, disruptions to care due to the lockdown, morbidity, hospitalization, the date and cause of death, and basic demographic and socioeconomic characteristics. We also embedded open-ended questions into the surveys to collect qualitative descriptions from patients about care disruptions faced. The survey instrument was extensively piloted and surveys were conducted by surveyors experienced in phone-based data collection and employed by JPAL South Asia, which also coordinated all local operations. We completed the first round of surveys between late May 2020 and mid-June 2020, and follow-up surveys in July and August with all patients alive at the time of the first survey to track complete mortality through July. To help put survey results into context, the field research team also conducted phone-based structured interviews with staff at 15 hospitals.

The respondents were typically medical staff with a management role. A mix of public and private hospitals from central and remote locations in 10 of Rajasthan’s 33 districts were selected. Interviews collected information on disruptions faced by the hospital due to the lockdown to corroborate and supplement patient reports of disruptions. The study was approved by the Institutional Review Boards at the Institute for Financial Management and Research (IFMR) in India and Stanford University in the United States.

2.2. Outcomes and measures

We measured disruptions to dialysis care by asking whether patients faced each of the following problems during the lockdown: their dialysis...
hospital was closed; it was open but refused to provide them services; they could not travel to their hospital due to lack of transport or curfews; they had to switch to a different hospital from their primary dialysis hospital; their hospital increased charges over the typical payment; they had difficulties obtaining their dialysis medicines. Reported dialysis hospital; their hospital increased charges over the typical payment; they had to switch to a different hospital from their primary dialysis hospital; they could not travel to their hospital due to lack of transport or curfews.

To track changes in monthly mortality over the months before and after the lockdown, we created a mortality time series between December 2019 and July 2020. We determined the month of death for all dead patients by cross-checking two measures - the exact month of death and the number of months that had lapsed since the death at the time of survey. We did not conduct complete autopsies, but did ask households whether the cause of death was related to a health condition, symptoms prior to death (the same questions used to measure morbidity in alive patients), and whether the patient or anyone in the household had tested COVID positive. This allowed us to ensure we were not counting entirely unrelated deaths, for example from accidents, to separate out COVID deaths, and to confirm that the included deaths are highly likely to be related to dialysis. Monthly mortality, or the likelihood of death, was calculated as the number of deaths each month as a share of people alive at the beginning of that month.

Morbidity and hospitalization were reported for the four weeks prior to the survey, in each round of the survey. A morbidity index was constructed from a PCA of indicators for whether the patient experienced the following symptoms that are known to follow disruptions to dialysis care and can be reported by patients: swelling of the face, hands, legs, or body; vomiting or nausea; extreme tiredness or weakness; difficulty breathing; difficulty urinating; and muscle cramps. The index was standardized over the sample. Hospitalization was an indicator for any in-patient hospital visit.

To examine heterogeneity in outcomes by socioeconomic and demographic characteristics, we created binary classifications for female, age under 45 years, lower caste group (scheduled caste or tribe), and low assets. Patients were classified as low asset if they had a below median score on an asset index created from a PCA of a list of assets they own, such as a motorcycle, television, or air-conditioner. Additionally, we geocoded all dialysis hospitals in the AB-MGRSBY program as well as the residence locations for 88% of surveyed patients using addresses in the administrative data that were verified by survey. We calculated the distance from patient residence to the district administrative headquarters, the largest city in the district, as a proxy for remoteness, and to the closest dialysis hospital as a proxy for distance from the health system. For heterogeneity analysis, we created binary classifications for above and below the median distance in the study sample, which was 45 km for distance to the city and 35 km for distance to a dialysis hospital.

2.3. Comparison cohort

Because the COVID-19 lockdown was implemented across all of India at the same time, there are no populations that were not subject to the lockdown in 2020 to use for comparison. Therefore, our analysis primarily focused on changes in mortality trends within our study cohort over the four months before and after the lockdown was imposed. In addition, we constructed a historical comparison cohort to allow us to account for potential seasonal trends or monthly fluctuations in mortality and to examine whether 2020 mortality follows historical trends. As discussed above, to create our main sample we used administrative insurance claims data to identify patients on dialysis between August and October 2019 and follow them through July 2020. To create the comparison cohort, we used the same claims data to identify all patients on dialysis under insurance between August and October 2018 and followed them through July 2019. This allowed us to compare the trend in outcomes between December 2019 and July 2020 in our main cohort to the trend in the same months in the previous year in the comparison cohort.

Because phone surveys with these patients would likely suffer from attrition and recall bias, we instead used the share of patients that permanently dropped out from dialysis care in the claims data each month to proxy for the share of people that died in that month. We have previously validated this measure of mortality. In mid-2018, we sampled 663 that had dropped out of the claims data (no claim for two months) and conducted phone surveys with their households to confirm the cause of dropout. Surveys confirmed that 20% were alive and had dropped out for reasons besides death (exiting the insurance program, out of state migration, kidney transplant, or discontinuation of treatment for financial reasons) and the remaining were dead. This analysis confirms that dropouts in the claims data are highly predictive of death and may be a reasonable proxy measure. Monthly mortality in the historical cohort was, therefore, calculated as the 80% of the share of all patients on dialysis each month that dropped out of treatment in that month. One concern is that the 80% death rate in the validation study may not apply many months later. Because the purpose of the analysis is to compare trends, rather than levels, across the two cohorts to see if the seasonal fluctuations rather than the lockdown are driving mortality increase, our results are not sensitive to what share of dropouts we count as deaths. As a check on this, we tested whether the difference between mortality March and May in 2020 was statistically different from the difference between proxy mortality in March and May in 2019. We also show the proxy mortality trend without the 20% adjustment in the supplement (Fig. S3). We also create a second comparison cohort using claims data and the same methods, but going back another year to check whether trends are stable as a robustness check. It remains possible that the true death rate in the comparison cohort fluctuated between December and July 2019 and our proxy is not capturing this. We discuss the limitations of this approach in the Discussion section.

2.4. Statistical analysis

To examine changes in monthly mortality before and after the lockdown, we estimated a non-parametric discrete-time logistic model with the probability of death as the outcome and binary indicators for each month from December 2019 to July 2020. We excluded October and November 2019 from the analysis because survey dropout was likely to be highest in these months and could bias mortality estimates, but complete death counts for the full period are provided in the supplement Table S3. Adjusted models included indicators for age above 45 years, female sex, lower caste group, and low assets, and continuous measures of months on dialysis and total dialysis visits at baseline. To examine historical mortality trends, we ran the same unadjusted model on the comparison cohort with indicators for each month from December 2018 to July 2019, as well as a model adjusted for age above 45 years and total dialysis visits prior to enrollment. Standard errors were clustered at the patient level in all models to account for autocorrelation.

To analyze the association between lockdown-related care disruptions and health outcomes, we restricted the sample to patients alive at the end of April (and, therefore, exposed to at least one month of the lockdown), and estimated linear OLS regressions, with heteroskedasticity-robust standard errors, of morbidity, hospitalization, and death between May and July on the care disruptions index. Adjusted
models included indicators for age above 45 years, female sex, low caste group, and low assets, as well as continuous measures of months on dialysis and total dialysis visits at baseline. Sensitivity to using logistic regression models was also assessed.

We also examined whether the lockdown had differential effects on care-seeking and outcomes by sex, age (above 45 years), lower caste, and low assets. First, we estimated bivariate and multivariate logistic regressions of an indicator for having experienced any disruption on binary indicators for each subgroup characteristic. Second, we calculated the percentage point change in monthly mortality between March and May for each subgroup from logistic regressions controlling for all other subgroup characteristics and dialysis history. Lastly, we estimated the association between care disruptions and health outcomes separately for each subgroup.

3. Results

We identified 3183 patients on dialysis under insurance between August and October 2019 across Rajasthan. Of these, 2234 (70.2%) had a reachable phone number, and 94% of them consented to participating, resulting in a study sample of 2110 patients (Supplementary Table S1). Attrition may be due to numbers being entered incorrectly in the insurance data, households changing numbers, or unused numbers being deactivated and reassigned to new households. Of the 1392 patients alive at the time of the first survey, 1177 (85%) completed a follow-up survey. Successfully surveyed patients were disproportionately male (69%), had a mean age of 46 years, and had been on dialysis for a year, with 5 visits per month on average, when they were enrolled into the study (Table 1). Surveyed patients were almost identical in these characteristics to patients not reached, but had been on dialysis for slightly longer, increasing our confidence that attrition did not meaningfully bias our sample (supplement Table S2). On average, patients lived 25 km from the nearest hospital providing dialysis care. The vast majority of patients (83%) were visiting a private hospital for their dialysis treatments.

3.1. Disruptions to dialysis care

Over 63% of patients reported a disruption in access to dialysis care during the lockdown (Fig. 1). 42% of patients reported being unable to reach their hospital due to travel barriers. Answers to open-ended questions indicated that travel barriers were largely due to difficulties finding transport and obtaining official exemptions from district administrative and health authorities to travel to the hospital. 15% of patients found the hospital was closed or refused to provide care, 11% report that pharmacies were stocked out of medicines and raised their prices, suggesting there were supply chain disruptions. As a result, 17% of patients could not obtain their necessary medicines. Patients faced a 172% increase in payments per visit, driven largely by increased charges at private hospitals. 22.2% of patients experienced a decline in monthly dialysis visits between March and April and the average decline was 6%. Hospital interviews confirmed patient reports, but also suggested that hospitals faced their own constraints. Seven of the 15 hospitals reported having to close during the lockdown due to staffing and supply shortages. Those that continued operating reported a substantial drop in patient visits, which they credited to transportation barriers, and larger hospitals reported receiving patients displaced from nearby hospitals that had closed.

3.2. Association between care disruptions and outcomes

Among patients alive at the end of April and exposed to at least one month of the lockdown, a 1SD increase in the care disruptions index results in a 0.17SD increase in the morbidity index (95% CI 0.13–0.22), and 2.1pp increase in the probability of hospitalization (95% CI 0.01–0.05), and 2.1pp increase in the probability of death (95% CI 0.00–0.04) in the period from May to July 2020 (Table 2). These effects are sizeable relative to an overall 14.2% hospitalization and 10.8% mortality hazard over those months. Controlling for sociodemographic characteristics and dialysis history did not change these relationships. They also remain robust to using logistic instead of OLS regression models for the binary hospitalization and death outcomes (Supplemental Table S5).

3.3. Changes in mortality trends

Monthly mortality declined steadily from December 2019 to March 2020 (Fig. 2), due to early deaths among the most vulnerable patients, such as the elderly and lower caste (supplement Fig. S1). Mortality in May 2020, after a full month of exposure to the lockdown, increased sharply to 4.37% (95% CI 3.33–5.40), a 1.70pp or 63.60% (95% CI 0.01–0.03) change relative to mortality in March, prior to the lockdown, which was 2.67% (95% CI 1.87–3.46). Controlling for sociodemographic characteristics and patient dialysis history increased this difference to 1.85pp (95% CI 0.01–0.03) or 67.77% (supplement Fig. S2). Mortality declined in June and July 2020, but never dropped below March levels, indicating that deaths in May were not simply a displacement of mortality from the subsequent two months. Because we did not reach all households in the follow-up survey, true mortality in this period may be higher than measured. Only four patients who died in June and July were reported testing positive for COVID-19. Excluding them reduces mortality to 3.16% in June and 2.69% in July.

We compare this to mortality over the same months in the previous year in the historical comparison cohort. The historical cohort followed a statistically similar trend between December 2018 and April 2019, but exhibited no increase in May 2019 or the subsequent months. The change in the historical cohort between March and May was 0.16pp (95% CI 0.01–0.02), which is 1.54pp (95% CI 0.01–0.34) smaller and statistically significantly different from the 1.67pp change in the main cohort over the same period (Supplemental Table S5). In supplementary analysis, the trend in the second comparison cohort one year further back, between December 2017 and July 2018, is almost identical to the 2018–2019 cohort, with no uptick in May, suggesting the trend in the comparison cohort is reliable (Supplemental Fig. S3). Comparison of trends in the study and historical cohorts suggests that the sharp increase in May 2020 is not explained by monthly or seasonal fluctuations and that, absent the lockdown, monthly mortality would have remained similar to or slightly below March levels in 2020, as it did in 2019.

To estimate total excess mortality in the four months following the COVID-19 lockdown, we calculated the difference between observed mortality between April and July 2020 and what mortality would have been if the March 2020 mortality probability of 2.67% had applied each
month. Out of 1532 patients alive at the end of March, 192 had died by the end of July (12.54% mortality), whereas 157 would have died had the March rate (10.25% mortality), resulting in 22.3% total estimated excess mortality in the four months following the lockdown (supplement Table S3). This is likely to be a conservative estimate, as both pre-lockdown trends and the historical comparison suggest that mortality would have continued to decline in the absence of the lockdown rather than remain at March 2020 levels.

3.4. Subgroup heterogeneity in lockdown effects

Although the lockdown was universal, its effects on care-seeking were worse for vulnerable and remote households. Being lower caste, poorer, and living further away from a city or a dialysis hospital had large and significant positive associations with the likelihood of facing any care disruption (Table 3). Poverty had the strongest relationship and remained significant in multivariate regressions controlling for other socioeconomic characteristics and dialysis history. Fig. 3 presents the change in mortality in May, relative to March, by subgroup. Underlying data are presented in Supplemental Table S6. The increase in mortality was largest and significant for females (3.64pp, 95% CI 0.52–10.77). The associations between the care disruptions index and morbidity, hospitalization, and death were also stronger for these subgroups (supplement Fig. S3). The greater disruptions to care faced by poorer and remote patients noted above could partly explain their worse outcomes, but we find no evidence that females experienced greater disruptions. An alternate explanation for high female mortality may be lower care-seeking by households, consistent with prior literature on gender bias in health care in India (Dupas and Jain, 2020; Kapoor et al., 2019; Shaikh et al., 2018). Females had fewer monthly dialysis visits at baseline (4.8 visits) relative to males (5.1 visits, p = 0.062), which could contribute to worse health prior to the lockdown. Additionally, care disruptions were associated with increased morbidity for both males and females, but with increased hospitalization only for males, and larger increases in mortality for females, suggesting that households may have been less likely to seek hospital care for females that faced complications (supplement Fig. S3).

4. Discussion

We studied the indirect effects of India’s COVID-19 lockdown on critical, chronic, non-COVID care and outcomes among a large cohort of low-income dialysis patients. Two-thirds of patients faced disruptions to their care during the lockdown. Travel barriers, hospital closures, service refusals, and difficulties obtaining medicines were common causes.
Patients infected with COVID-19 in India have been documented, if this infection and complications and excess mortality among dialysis patients experienced a decrease in monthly dialysis visits, and faced any lockdown-related care disruption. Lockdown-related disruptions to dialysis care were significantly positively associated with morbidity, hospitalization, and mortality in the months just after its imposition. After the nationwide COVID-19 lockdown, increased sharply and was 1.70pp higher than in March 2020. The timing and size of the increase in mortality in the study through March, largely before the virus had spread widely, and was greater among patients under age 45 than among older patients who have higher COVID-19 mortality risk. Therefore, we believe our estimates are capturing the indirect effects of the pandemic through lockdown-related disruptions to care. Nevertheless, given that COVID-19 testing rates in India were relatively low at the time of the study, we cannot rule out the possibility that it contributed to the deaths we measured.

As a result, 23% of patients switched away from their primary hospital, 22% experienced a decrease in monthly dialysis visits, and 11% faced increased treatment charges. Lockdown-related disruptions to dialysis care were significantly positively associated with morbidity, hospitalization, and mortality in the months just after its imposition. After declining steadily from December, mortality in May 2020, after a month of exposure to the lockdown, increased sharply and was 1.70pp higher than in March 2020. Mortality for a similar cohort over the same months in the previous year, proxied by permanent dropout from dialysis care, followed a steady downward trend between December and July. The timing and size of the increase in mortality in May 2020 relative to pre-lockdown trends in 2020, as well as to trends in estimated mortality in the previous year, strongly suggest that it was due to the nationwide COVID-19 lockdown. Estimated overall excess mortality in the four months after imposition of the lockdown was 22%.

The excess mortality we measure is unlikely to be due to COVID-19 infections. Although patients on dialysis are at higher risk of COVID-19 infection and complications and excess mortality among dialysis patients infected with COVID-19 in India has been documented, if this were driving mortality in our setting, we would expect deaths to increase over time as the virus spread and to affect older patients more (Gansevoort and Hilbrands, 2020; Kakkanattu et al., 2021). However, the increase in mortality was largest in May, soon after the lockdown and before the virus had spread widely, and was greater among patients under age 45 than among older patients who have higher COVID-19 mortality risk. Women also experience a larger increase in mortality than males do (though the comparison is not statistically significant), which may be because they receive worse care. It is critical that future pandemic control efforts take these distributional consequences into account and put in place extra protections for populations that have limited financial and geographic access to health services. Broader efforts to strengthen the health system so that it is responsive to the health needs of vulnerable populations is important for ensuring they do not disproportionately bear the burden of future pandemics.

Our study population is all dialysis patients in the AB-MGRSBY government health insurance program. Given that the poorest half of Rajasthan’s population is enrolled in AB-MGRSBY, our study is representative of close to all low-income dialysis patients in the state. Total mortality in the study through March, largely before the pandemic, was 27.4% and through July was 34.7% (Supplemental Table S3). In comparison, another study of dialysis patients in India reports a substantially lower two-year mortality rate of 19.8% (Chandrashekar et al., 2014). While our analysis is restricted to one type of critical chronic care in one state, our findings are likely to be indicative of the serious but largely undocumented health effects of severe disruptions to dialysis and a range of similar critical chronic care services in other states in India. A 2019 study estimated that there are approximately 175,000 patients on chronic dialysis across India and recent research suggests that a large

Table 3

| Outcome: Faced Any Care Disruption | Bivariate | Multivariate |
|-----------------------------------|----------|-------------|
| | OR | 95% CI | P | OR | 95% CI | P |
| Female | 0.974 | 0.780-1.216 | 0.815 | 0.979 | 0.768-1.247 | 0.862 |
| 45yrs or younger | 1.143 | 0.932-1.402 | 0.200 | 1.063 | 0.850-1.330 | 0.593 |
| Lower caste | 1.333 | 1.003-1.773 | 0.048 | 1.152 | 0.849-1.563 | 0.363 |
| Low assets | 1.618 | 1.315-1.990 | <0.001 | 1.495 | 1.191-1.876 | 0.001 |
| Far from city | 1.302 | 1.038-1.635 | 0.023 | 1.212 | 0.962-1.528 | 0.103 |
| Far from hospital | 1.360 | 0.995-1.861 | 0.054 | 1.269 | 0.923-1.744 | 0.142 |

The solid line presents monthly likelihood of death, or the share of people still alive that die in each month, for the surveyed cohort, from an unadjusted discrete time logistic regression model with indicators for each month from December 2019 through July 2020. Vertical bars represent 95% confidence intervals. The dashed line presents the monthly hazard for the comparison cohort of patients on dialysis in August-October 2018 from a similar model with indicators for each month from December 2018 through July 2019. Mortality estimates have been converted into percentage terms for ease of interpretation. Covariate-adjusted models in the online supplement look almost identical.
share of these patients suffered severe disruptions to their care, similar to those we document (Jha et al., 2019; Ramachandran and Jha, 2020). A large multicenter study reported that 28% of patients had missed one or more dialysis visits, and that both outpatient and inpatient services were reduced due to the lockdown (Prasad et al., 2020). A nationwide analysis of dialysis patients under government health insurance programs targeting low-income households, a population very comparable to the one we study, finds a 6% reduction in dialysis visits, very similar to our results (Smith et al., 2020). One study of COVID-19 mortality among dialysis patients also finds evidence of increased mortality among COVID-19-negative patients, which may be attributable to care disruptions very similar to those reported in this study (Kakkanattu et al., 2021). Evidence is also emerging of disruptions to critical care for other conditions, such as cancers, cardiovascular emergencies, and TB in India (Cillonì et al., 2020; Kusuma et al., 2021; Ranganathan et al., 2021; Singh et al., 2021). For example, the same analysis of government health insurance programs finds a 64% decline in oncology care and an 80% decrease in critical cardiovascular surgeries (Smith et al., 2020).

While the precise magnitude of health effects of care disruptions may vary by condition, our results suggest they may go undetected without careful research tracking cause-specific morbidity and mortality. Broader efforts to increase death registration rates, improve the timeliness and quality of mortality survey data, and ensure cause of death is better recorded will be important for better and earlier tracking of mortality in future.

A strength of this study is the use of existing administrative government health insurance claims data to rapidly identify and remotely survey a large sample of poor dialysis patients in need of critical care during the lockdown. A limitation of this approach is the substantial attrition between identified dialysis patients and those reached for survey by phone due to patient phone numbers entered incorrectly in the claims data, households switching phone numbers, and unused numbers being deactivated. However, attrition rates are similar to those in other phone surveys and surveyed patients were statistically similar to those not reached, increasing confidence that attrition did not bias our study sample (Singh et al., 2021). Furthermore, these issues are most likely to affect patients that died soon after October 2019 and cannot explain the increased mortality in May 2020. Another limitation is that our outcomes are based on self-reported data and not clinical measures, which were infeasible due to the pandemic. However, our primary outcome is mortality, which is likely to be reliably reported, and the recall period for all outcomes was relatively short. However, to create a comparison cohort unaffected by the lockdown we use 80% of dropouts from the claims data as a proxy measure for mortality. We have validated this measure and found that it is highly predictive of death, and the comparison and main cohort trends pre-lockdown are very similar, suggesting the measure is not way off, but it may not measure mortality levels and fluctuations precisely. However, the steady pre-lockdown declining trend, the specific timing of the 2020 uptick, exactly a month after the lockdown, and the strong association between care disruptions and mortality, hospitalization, and morbidity strongly suggest that the effects we observe in 2020, even setting aside the comparison cohort, are due to the lockdown and not other fluctuations.

Finally, as we only measure mortality through July, our estimates may
be a lower bound on the full health costs of the lockdown. We found that disruptions to dialysis were lower but persistent in July and August, after the lockdown was eased, suggesting that adverse health effects may have continued to unfold past the study period (supplement Fig. S4).

An important outstanding question concerns the extent and health impacts of disruptions caused by the massive second wave of COVID-19 infections that India experienced, with over 400,000 new daily cases in early May 2021 (Johns Hopkins, 2021). Although there has been no national lockdown, reports suggest access to non-COVID care has been severely affected because health facilities are heavily focused on COVID-19 care or refuse to provide critical chronic care to COVID-19-positive patients (Aljazeera, 2021; The Guardian, 2021). Our results from the first wave provide strong reason to think that the second wave will have sizeable impacts on non-COVID morbidity and mortality among patients needing critical care, adding to the heavy toll of the pandemic. It is critical that these effects be carefully measured. Our study demonstrates that phone surveys combined with administrative data from existing government health programs provide a powerful way of measuring health impacts.

Lockdowns can reduce COVID-19 transmission (Figueiredo et al., 2020; Flaxman et al., 2020; Islam et al., 2020, Thayer et al., 2021). However, they have substantial indirect health and economic costs that may outweigh their benefits relative to other pandemic control strategies in some contexts (Cash and Patel, 2020; Douglas et al., 2020; Haug et al., 2020; Modesti et al., 2020). The tradeoffs are complex and the optimal policy, as well as the full range of costs and benefits, will depend on local conditions (The Lancet COVID-19 Commission Task Force, 2021). Our findings highlight the unintended consequences of India’s lockdown on critical non-COVID health services that must be taken into account in the implementation of future policy efforts to control the spread of pandemics and the importance of preparing health systems better (Abdel-Kader and Unruh, 2009 for future disasters or outbreaks).

Credit author statement

Radhika Jain: Conceptualization; Methodology; Formal analysis; Visualization; Writing – original draft; Writing – review & editing; Supervision; Funding acquisition. Pascale Dupas: Conceptualization; Methodology; Writing – review & editing; Supervision; Funding acquisition

Funding

This research was funded by a grant from the Bill and Melinda Gates Foundation, awarded through the J-PAL CaTCH Initiative’s special COVID-19 funding window. The funder had no role in the design or execution of the research.

Declaration of competing interest

Authors declare no competing interests.

Acknowledgments

We are grateful to Ambika Chopra, Mustufa Patel, and Mantantas Hussain for their excellent and dedicated research assistance and to Putul Gupta for outstanding research management.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.socscimed.2022.114762.

References

Abdel-Kader, K., Unruh, M.L., 2009. Disaster and end-stage renal disease: targeting health care for improved outcomes. Kidney Int. 75 (11), 1131–1135. Jun 1. Aljazeera, 2021. India COVID Crisis: ‘Our Mother Has Two Swords over Her Head’‘, 3 May, https://www.aljazeera.com/features/2021/5/3/india-covid-crisis-our-mother-has-two-swords-over-her-head. Anderson, A.H., Cohen, A.J., Sperti, C.A., et al., 2009. Missed dialysis sessions and hospitalization in hemodialysis patients after Hurricane Katrina. Kidney Int. 75 (11), 1202-1208. Jun1. Bambra, C., Riordan, R., Ford, J., Matthews, F., 2020. The COVID-19 pandemic and health inequalities. J. Epidemiol. Community Health. Jun 12. Beaney, T., Clarke, J.M., Jain, V., Goletstone, A.K., Lyons, G., Salmon, D., Majeed, A., 2020. Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide? J. R. Soc. Med. 113 (9), 329–334. Sep. Bikov, B., Purcell, C.A., Lewey, A.S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O.M., Arafieh, M., Agarwal, S.K., Agedelo-Botero, M., Ahmadian, E., 2020. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 (10225), 793–793. Feb 29. Cash, R., Patel, V., 2020. Has COVID-19 subverted global health? Lancet 395 (10238), 1687–1688. May 30. Chandrasekhar, A., Ramakrishnan, S., Ranganathan, D., 2014. Survival analysis of patients on maintenance hemodialysis. Indian J. Nephrol. 24 (4), 206. Jul. Cillon, I., Fu, H., Vesga, J.F., Dowdy, D., Pretorius, C., Ahmedov, S., Nair, S.A., Monseaga, A., Masini, E., Sahu, S., Arainimpanthy, N., 2020. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 28, 100603. Nov 1. Douglas, M., Katiirkeddi, S.V., Talbult, M., McKee, M., McCartney, G., 2020. Mitigating the wider health effects of covid-19 pandemic response. BMJ 369, Apr 27. Du, M., Jain, R., 2020. Gender Disparities in Government Health Insurance in India. Working paper. Figueiredo, A.M., Daponte Codina, A., Figueiredo, M., Saiez, M., Cabrera Leon, A., 2020. Impact of Lockdown on COVID-19 Incidence and Mortality in China: an Interrupted Time Series Study. Bull World Health Organ. 2020 Flaxman, S., Mishra, S., Gandy, A., Unwin, H.J., Mellan, T.A., Coupland, H., Whitaker, C., Zhu, H., Berah, T., Eaton, J.W., Monod, M., 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584 (7820), 257-261. Aug. Gansevoort, R.T., Hilbrands, L.B., 2020. CKD is a key risk factor for COVID-19 mortality. Nat. Rev. Nephrol. 16 (12), 705–706. Dec. Hale, T., Petherick, A., Phillips, T., Webster, S., 2020. Variation in Government Responses to COVID-19. Blavatnik school of government working paper, May 27-31. Haug, N., Geyerhofer, L., Londie, A., Dervic, E., Desvars-Larrive, A., Loreto, V., Pinior, B., Thurner, S., Klimek, P., 2020. Ranking the effectiveness of worldwide COVID-19 government interventions. Nature human behavior. Nov 161-0. Johns Hopkins University. Johns Hopkins coronavirus resource center. https://coronavirus.jhu.edu/. (Accessed 10 June 2021). Indian Express, 2020. Private Hospitals Can’t Refuse Critical Patients or Insist on Testing All for COVID-19: Centre, 28 April. https://www.newindianexpress.com/indianews/2020/apr/28/private-hospitals-cant-refuse-critical-patients-or-insist-on-testing-all-for-covid-19-centre-2136540.html. Indian Express, 2020. How Healthcare Became Unaffordable for Non-COVID Patients during First, Says RBI, 18 May. https://indianexpress.com/article/business/covid-second-wave-indian-economy-ch-7519301/. Indian Spend, 2020a. How Healthcare Became Unaffordable for Non-COVID Patients during the Pandemic, 19 June. https://www.indianspend.com/how-healthcare-became-unaffordable-for-non-covid-patients-during-the-pandemic. Indian Spend, 2020b. COVID-19 disrupted India’s routine health services. IndianSpend, 27 August. https://www.indianspend.com/covid-19-disrupted-indias-routine-health-services. Islam, N., Sharp, S.J., Chowell, G., Shabnam, S., Kawachi, I., Lacey, B., Massaro, J.M., D’Agostino, R.B., White, M., 2020. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ 370. Jul 15. Jain, R., Chopra, A., et al., 2021 Jul 13. COVID-19 related immunization disruptions in Rajasthan, India: a retrospective observational study. Vaccine 39 (31), 4343–4350. Jha, P., Gajalakshmi, V., Gupta, P.C., et al., 2005. Prospective study of one million deaths worldwide? J. R. Soc. Med. 113 (9), 329–337. Jan 1. Kakkanattu, T.J., Sankarsabbuji, S., Yadav, A.K., Kundi, M., Bg, M.G., Kumar, V., Krishna, S., Konal, A., Jha, V., 2020. Outcome and determinants of outcome of COVID-19 infection among hemodialysis patients: findings from a national dialysis network registry. Indian J. Nephrol. 26 (5), 1429–1432. May 1. Kapoor, M., Agraval, D., Ravi, S., et al., 2019. Missing female patients: an observational analysis of sex ratio among outpatients in a referral tertiary care public hospital in India. BMJ Open 9 (8), e026850. Aug 1. Kiang, M.V., Iritzarry, R.A., Buckee, C.O., Bahlaz, S., 2020. Every body counts: measuring mortality from the COVID-19 pandemic. Ann. Intern. Med. Sep. 11. Kusuma, D., Pradeepa, R., Khwaja, K.I., Hasan, M., Siddiqui, S., Mahmood, S., Shah, S., de Silva, D., de Silva, L., 2020. Impact of Lockdown on COVID-19 incidence and mortality in South Asia. Kidney Int. 95 (1), 31–37. Jan 1. Mosneaga, A., Masini, E., Sahu, S., Arinimpanthy, N., 2020. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 28, 100603. Nov 1. Whittaker, C., Zhu, H., Berah, T., Eaton, J.W., Monod, M., 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584 (7820), 257-261. Aug.
Ministry of Home Affairs Order No 40-3/2020-D Dated 24.03, 2020. https://www.mha.gov.in/sites/default/files/Guidelines.pdf.

Modesti, P.A., Wang, J., Damasceno, A., Agyemang, C., Van Bortel, L., Persu, A., Zhao, D., Jarraya, F., Marzotti, I., Bamoshmoosh, M., Parati, G., 2020. Indirect implications of COVID-19 prevention strategies on non-communicable diseases. BMC Med. 18 (1), 1–6. Dec.

New York Times, 2020. 8 Hospitals in 15 Hours: A Pregnant Woman’s Crisis in the Pandemic, 12 July. https://www.nytimes.com/2020/06/21/world/asia/coronavirus-india-hospitals-pregnant.html.

Prasad, N., Bhatt, M., Agarwal, S.K., et al., 2020. The adverse effect of COVID pandemic on the care of patients with kidney diseases in India. Kidney International Reports. Jul 6.

Ramachandran, R., Jha, V., 2020. Adding insult to injury: kidney replacement therapy during COVID-19 in India. Kidney Int. Apr 25.

Ranganathan, P., Sengar, M., Chinnaswamy, G., et al., 2021. Impact of COVID-19 on cancer care in India: a cohort study. Lancet Oncol. May 27.

Sample Registration System (SRS) Bulletins. Office of the registrar general and census commissioner. https://censusindia.gov.in/vital_statistics/SRS_Bulletins/Bulletins.html.

Saran, R., Bragg-Gresham, J.L., Rayner, H.C., et al., 2003. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 64 (1), 254–262. Jul 1.

Setel, P., AbouZahr, C., Atubehire, E.B., et al., 2020. Mortality surveillance during the COVID-19 pandemic. Bull. World Health Organ. 98 (6), 374. Jun 1.

Shaikh, M., Peters, S.A., Woodward, M., et al., 2018. Sex differences in utilisation of hospital care in a state-sponsored health insurance programme providing access to free services in South India. BMJ Global Health 3 (3), e000859. Jun 1.

Sharma, A., Rana, S.K., Prinja, S., Kumar, R., 2016. Quality of health management information system for maternal & child health care in Haryana state, India. PLoS One 11 (2), e0148449.

Singh, K., Kondal, D., Mohan, S., Jaganathan, S., et al., 2021. Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study. BMC Publ. Health 21 (1), 1–5. Dec.

Smith, G., Naib, P., Sehgal, P., Chhabhra, S., 2020. PM-JAY under Lockdown: Evidence on Utilization Trends. PM-JAY Policy Brief 8. National Health Authority, Thayer, W.M., Hasan, M.Z., Santhi, P., Gupta, S., 2021. An interrupted time series analysis of the lockdown policies in India: a national-level analysis of COVID-19 incidence. Health Pol. Plan. 36 (5), 620–629. Jun.

The Guardian, 2021. Medics’ Anger as Delhi Orders Most Beds in Private Hospitals Be Reserved for Covid Cases, 15 April. https://www.theguardian.com/global-development/2021/apr/15/medics-anger-as-delhi-orders-private-hospitals-be-reserved-for-covid-cases.

The Lancet, 2020. India under COVID-19 lockdown. Lancet 395 (10233), 1315. Apr 25.

The Lancet, 2021. India’s COVID-19 emergency. Lancet 397 (10286), 1683. May.

The Lancet COVID-19 Commission India Task Force, 2021. Country-wide Containment Strategies for Reducing COVID-19 Cases in India. April. https://static1.squarespace.com/static/5ef3652ab722df11eb2e8a5d/t/60a3cf08d1c124480a44c19/1621348107249/India+TF+Country-wide+Containment+Strategies+April+2021.pdf.

Zoraster, R., Vanholder, R., Sever, M.S., 2007. Chronic dialysis patients. American Journal of Disaster Medicine 2 (2), 96–106. Mar 1.